Which has stronger valuation and earnings, DMRA or LRMR?

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Damora Therapeutics, Inc. Common Stock N/A N/A -$209.84M -$5.58 N/A Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A

Is DMRA or LRMR more profitable?

Larimar Therapeutics' return on equity of -134.14% beat Damora Therapeutics, Inc. Common Stock's return on equity. Company Net Margins Return on Equity Return on Assets Damora Therapeutics, Inc. Common Stock N/A -428.30% -114.62% Larimar Therapeutics N/A -134.14% -96.00%

Does the media prefer DMRA or LRMR?

In the previous week, Damora Therapeutics, Inc. Common Stock and Damora Therapeutics, Inc. Common Stock both had 3 articles in the media. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.49 beat Larimar Therapeutics' score of 0.00 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Damora Therapeutics, Inc. Common Stock 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, TRLV or LRMR?

Trulieve Cannabis has higher revenue and earnings than Larimar Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Trulieve Cannabis $1.17B 1.43 N/A N/A N/A Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A

Is TRLV or LRMR more profitable?

Trulieve Cannabis' return on equity of 0.00% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Trulieve Cannabis N/A N/A N/A Larimar Therapeutics N/A -134.14% -96.00%

Does the media favor TRLV or LRMR?

In the previous week, Trulieve Cannabis and Trulieve Cannabis both had 3 articles in the media. Trulieve Cannabis' average media sentiment score of 0.65 beat Larimar Therapeutics' score of 0.00 indicating that Trulieve Cannabis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Trulieve Cannabis 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LRMR or MAZE more profitable?

Maze Therapeutics' return on equity of -36.62% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -134.14% -96.00% Maze Therapeutics N/A -36.62% -31.78%

Does the media favor LRMR or MAZE?

In the previous week, Larimar Therapeutics had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 3 mentions for Larimar Therapeutics and 2 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.09 beat Larimar Therapeutics' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maze Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LRMR or VIR?

In the previous week, Larimar Therapeutics and Larimar Therapeutics both had 3 articles in the media. Vir Biotechnology's average media sentiment score of 1.22 beat Larimar Therapeutics' score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vir Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, LRMR or MPLT?

Larimar Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Larimar Therapeutics N/A N/A -$165.67M -$2.06 N/A Maplight Therapeutics N/A N/A -$161.15M -$40.99 N/A

Is LRMR or MPLT more profitable?

Maplight Therapeutics' return on equity of 0.00% beat Larimar Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Larimar Therapeutics N/A -134.14% -96.00% Maplight Therapeutics N/A N/A N/A

Does the media refer more to LRMR or MPLT?

In the previous week, Larimar Therapeutics had 2 more articles in the media than Maplight Therapeutics. MarketBeat recorded 3 mentions for Larimar Therapeutics and 1 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.34 beat Larimar Therapeutics' score of 0.00 indicating that Maplight Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Larimar Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Maplight Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Larimar Therapeutics (LRMR) Competitors

$3.83 +0.13 (+3.51%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$3.80 -0.02 (-0.65%)

As of 07/20/2026 07:34 PM Eastern

Compare

LRMR vs. DMRA, TRLV, MAZE, VIR, and MPLT

Should you buy Larimar Therapeutics stock or one of its competitors? MarketBeat compares Larimar Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Larimar Therapeutics include Damora Therapeutics, Inc. Common Stock (DMRA), Trulieve Cannabis (TRLV), Maze Therapeutics (MAZE), Vir Biotechnology (VIR), and Maplight Therapeutics (MPLT). These companies are all part of the "pharmaceutical products" industry.

How does Larimar Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, Damora Therapeutics, Inc. Common Stock and Damora Therapeutics, Inc. Common Stock both had 3 articles in the media. Damora Therapeutics, Inc. Common Stock's average media sentiment score of 0.49 beat Larimar Therapeutics' score of 0.00 indicating that Damora Therapeutics, Inc. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Damora Therapeutics, Inc. Common Stock	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Damora Therapeutics, Inc. Common Stock has a beta of 1.46, meaning that its stock price is 46% more volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

Damora Therapeutics, Inc. Common Stock is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Damora Therapeutics, Inc. Common Stock	N/A	N/A	-$209.84M	-$5.58	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

14.2% of Damora Therapeutics, Inc. Common Stock shares are owned by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are owned by institutional investors. 0.4% of Damora Therapeutics, Inc. Common Stock shares are owned by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Damora Therapeutics, Inc. Common Stock currently has a consensus target price of $42.43, suggesting a potential upside of 28.61%. Larimar Therapeutics has a consensus target price of $12.71, suggesting a potential upside of 231.97%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Damora Therapeutics, Inc. Common Stock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Damora Therapeutics, Inc. Common Stock	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

Larimar Therapeutics' return on equity of -134.14% beat Damora Therapeutics, Inc. Common Stock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Damora Therapeutics, Inc. Common Stock	N/A	-428.30%	-114.62%
Larimar Therapeutics	N/A	-134.14%	-96.00%

Summary

Larimar Therapeutics beats Damora Therapeutics, Inc. Common Stock on 10 of the 12 factors compared between the two stocks.

How does Larimar Therapeutics compare to Trulieve Cannabis?

Trulieve Cannabis (NYSE:TRLV) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

Trulieve Cannabis has higher revenue and earnings than Larimar Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trulieve Cannabis	$1.17B	1.43	N/A	N/A	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

Trulieve Cannabis' return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trulieve Cannabis	N/A	N/A	N/A
Larimar Therapeutics	N/A	-134.14%	-96.00%

In the previous week, Trulieve Cannabis and Trulieve Cannabis both had 3 articles in the media. Trulieve Cannabis' average media sentiment score of 0.65 beat Larimar Therapeutics' score of 0.00 indicating that Trulieve Cannabis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Trulieve Cannabis	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.9% of Larimar Therapeutics shares are owned by institutional investors. 3.8% of Trulieve Cannabis shares are owned by company insiders. Comparatively, 4.5% of Larimar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Trulieve Cannabis currently has a consensus price target of $15.00, indicating a potential upside of 71.84%. Larimar Therapeutics has a consensus price target of $12.71, indicating a potential upside of 231.97%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Trulieve Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trulieve Cannabis	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09

Summary

Larimar Therapeutics beats Trulieve Cannabis on 6 of the 10 factors compared between the two stocks.

How does Larimar Therapeutics compare to Maze Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Maze Therapeutics (NASDAQ:MAZE) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Larimar Therapeutics currently has a consensus price target of $12.71, suggesting a potential upside of 231.97%. Maze Therapeutics has a consensus price target of $66.00, suggesting a potential upside of 132.64%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Larimar Therapeutics is more favorable than Maze Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Maze Therapeutics	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00

Larimar Therapeutics has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market. Comparatively, Maze Therapeutics has a beta of 2.14, meaning that its stock price is 114% more volatile than the broader market.

Maze Therapeutics has higher revenue and earnings than Larimar Therapeutics. Maze Therapeutics is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Maze Therapeutics	$167.50M	9.37	-$131.12M	-$2.53	N/A

Maze Therapeutics' return on equity of -36.62% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Maze Therapeutics	N/A	-36.62%	-31.78%

In the previous week, Larimar Therapeutics had 1 more articles in the media than Maze Therapeutics. MarketBeat recorded 3 mentions for Larimar Therapeutics and 2 mentions for Maze Therapeutics. Maze Therapeutics' average media sentiment score of 1.09 beat Larimar Therapeutics' score of 0.00 indicating that Maze Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maze Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.9% of Larimar Therapeutics shares are owned by institutional investors. 4.5% of Larimar Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Maze Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Maze Therapeutics beats Larimar Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Larimar Therapeutics compare to Vir Biotechnology?

Larimar Therapeutics (NASDAQ:LRMR) and Vir Biotechnology (NASDAQ:VIR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, media sentiment, institutional ownership and risk.

91.9% of Larimar Therapeutics shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Larimar Therapeutics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.62, indicating that its stock price is 62% more volatile than the broader market.

Larimar Therapeutics has higher earnings, but lower revenue than Vir Biotechnology. Vir Biotechnology is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Vir Biotechnology	$68.56M	22.70	-$437.99M	-$3.13	N/A

Larimar Therapeutics presently has a consensus target price of $12.71, suggesting a potential upside of 231.97%. Vir Biotechnology has a consensus target price of $20.88, suggesting a potential upside of 126.16%. Given Larimar Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Larimar Therapeutics is more favorable than Vir Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Vir Biotechnology	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Larimar Therapeutics has a net margin of 0.00% compared to Vir Biotechnology's net margin of -638.88%. Vir Biotechnology's return on equity of -53.31% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Vir Biotechnology	-638.88%	-53.31%	-41.76%

In the previous week, Larimar Therapeutics and Larimar Therapeutics both had 3 articles in the media. Vir Biotechnology's average media sentiment score of 1.22 beat Larimar Therapeutics' score of 0.00 indicating that Vir Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vir Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Larimar Therapeutics beats Vir Biotechnology on 9 of the 14 factors compared between the two stocks.

How does Larimar Therapeutics compare to Maplight Therapeutics?

Larimar Therapeutics (NASDAQ:LRMR) and Maplight Therapeutics (NASDAQ:MPLT) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Maplight Therapeutics' return on equity of 0.00% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Larimar Therapeutics	N/A	-134.14%	-96.00%
Maplight Therapeutics	N/A	N/A	N/A

In the previous week, Larimar Therapeutics had 2 more articles in the media than Maplight Therapeutics. MarketBeat recorded 3 mentions for Larimar Therapeutics and 1 mentions for Maplight Therapeutics. Maplight Therapeutics' average media sentiment score of 0.34 beat Larimar Therapeutics' score of 0.00 indicating that Maplight Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Maplight Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Larimar Therapeutics currently has a consensus price target of $12.71, suggesting a potential upside of 231.97%. Maplight Therapeutics has a consensus price target of $39.73, suggesting a potential upside of 10.38%. Given Larimar Therapeutics' higher probable upside, analysts clearly believe Larimar Therapeutics is more favorable than Maplight Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.09
Maplight Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	5 Strong Buy rating(s)	3.12

91.9% of Larimar Therapeutics shares are held by institutional investors. 4.5% of Larimar Therapeutics shares are held by insiders. Comparatively, 3.8% of Maplight Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Larimar Therapeutics is trading at a lower price-to-earnings ratio than Maplight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A
Maplight Therapeutics	N/A	N/A	-$161.15M	-$40.99	N/A

Summary

Maplight Therapeutics beats Larimar Therapeutics on 8 of the 13 factors compared between the two stocks.

Get Larimar Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LRMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LRMR vs. The Competition

Export

Metric	Larimar Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$384.37M	$3.07B	$6.89B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-1.86	20.20	27.06	23.94
Price / Sales	N/A	340.68	514.89	90.87
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	4.07	4.20	10.66	6.14
Net Income	-$165.67M	$65.94M	$3.60B	$331.74M
7 Day Performance	2.96%	-3.05%	-1.23%	-1.81%
1 Month Performance	5.28%	-1.30%	1.11%	-1.44%
1 Year Performance	17.48%	15.22%	23.65%	16.33%

Larimar Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LRMR Larimar Therapeutics	3.5787 of 5 stars	$3.83 +3.5%	$12.71 +232.0%	+19.3%	$384.37M	N/A	N/A	30
DMRA Damora Therapeutics, Inc. Common Stock	2.7208 of 5 stars	$28.00 -1.9%	$42.43 +51.5%	+818.9%	$1.76B	N/A	N/A	40	News Coverage
TRLV Trulieve Cannabis	3.7745 of 5 stars	$8.96 +3.9%	N/A	N/A	$1.72B	$1.17B	N/A	9,000	Analyst Forecast
MAZE Maze Therapeutics	2.0404 of 5 stars	$29.18 -4.5%	$66.00 +126.2%	+59.6%	$1.69B	$167.50M	N/A	121	Positive News
VIR Vir Biotechnology	2.5497 of 5 stars	$9.72 -2.4%	$20.88 +114.8%	+70.6%	$1.68B	$68.56M	N/A	580	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LRMR) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Larimar Therapeutics (LRMR) Competitors

LRMR vs. DMRA, TRLV, MAZE, VIR, and MPLT

How does Larimar Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Summary

How does Larimar Therapeutics compare to Trulieve Cannabis?

Summary

How does Larimar Therapeutics compare to Maze Therapeutics?

Summary

How does Larimar Therapeutics compare to Vir Biotechnology?

Summary

How does Larimar Therapeutics compare to Maplight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Larimar Therapeutics (LRMR) Competitors

LRMR vs. DMRA, TRLV, MAZE, VIR, and MPLT

How does Larimar Therapeutics compare to Damora Therapeutics, Inc. Common Stock?

Does the media prefer DMRA or LRMR?

Which has more risk and volatility, DMRA or LRMR?

Which has stronger valuation and earnings, DMRA or LRMR?

Do insiders & institutionals hold more shares of DMRA or LRMR?

Do analysts recommend DMRA or LRMR?

Is DMRA or LRMR more profitable?

Summary

How does Larimar Therapeutics compare to Trulieve Cannabis?

Which has preferable valuation and earnings, TRLV or LRMR?

Is TRLV or LRMR more profitable?

Does the media favor TRLV or LRMR?

Do insiders and institutionals have more ownership in TRLV or LRMR?

Do analysts recommend TRLV or LRMR?

Summary

How does Larimar Therapeutics compare to Maze Therapeutics?

Do analysts prefer LRMR or MAZE?

Which has more risk and volatility, LRMR or MAZE?

Which has preferable earnings and valuation, LRMR or MAZE?

Is LRMR or MAZE more profitable?

Does the media favor LRMR or MAZE?

Do institutionals and insiders hold more shares of LRMR or MAZE?

Summary

How does Larimar Therapeutics compare to Vir Biotechnology?

Do insiders & institutionals hold more shares of LRMR or VIR?

Which has more volatility and risk, LRMR or VIR?

Which has stronger earnings and valuation, LRMR or VIR?

Do analysts recommend LRMR or VIR?

Is LRMR or VIR more profitable?

Does the media prefer LRMR or VIR?

Summary

How does Larimar Therapeutics compare to Maplight Therapeutics?

Is LRMR or MPLT more profitable?

Does the media refer more to LRMR or MPLT?

Do analysts prefer LRMR or MPLT?

Do insiders and institutionals have more ownership in LRMR or MPLT?

Which has better valuation & earnings, LRMR or MPLT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LRMR vs. The Competition

Larimar Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools